Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,721 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer.
Hasegawa H, Taniguchi H, Nakamura Y, Kato T, Fujii S, Ebi H, Shiozawa M, Yuki S, Masuishi T, Kato K, Izawa N, Moriwaki T, Oki E, Kagawa Y, Denda T, Nishina T, Tsuji A, Hara H, Esaki T, Nishida T, Kawakami H, Sakamoto Y, Miki I, Okamoto W, Yamazaki K, Yoshino T. Hasegawa H, et al. Among authors: kato t, kato k. Cancer Sci. 2021 Jan;112(1):314-322. doi: 10.1111/cas.14693. Epub 2020 Nov 20. Cancer Sci. 2021. PMID: 33075166 Free PMC article.
First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
Tsuji Y, Satoh T, Tsuji A, Muro K, Yoshida M, Nishina T, Nagase M, Komatsu Y, Kato T, Miyata Y, Mizutani N, Hashigaki S, Lechuga MJ, Denda T. Tsuji Y, et al. Among authors: kato t. Cancer Sci. 2012 Aug;103(8):1502-7. doi: 10.1111/j.1349-7006.2012.02320.x. Epub 2012 Jun 14. Cancer Sci. 2012. PMID: 22537162 Free PMC article. Clinical Trial.
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M. Hazama S, et al. Among authors: kato t. Cancer Sci. 2013 Dec;104(12):1662-9. doi: 10.1111/cas.12283. Epub 2013 Oct 27. Cancer Sci. 2013. PMID: 24033692 Free PMC article. Clinical Trial.
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Yamazaki K, Kuwano H, Ojima H, Otsuji T, Kato T, Shimada K, Hyodo I, Nishina T, Shirao K, Esaki T, Ohishi T, Denda T, Takeuchi M, Boku N. Yamazaki K, et al. Among authors: kato t. Cancer Chemother Pharmacol. 2015 Mar;75(3):569-77. doi: 10.1007/s00280-015-2676-0. Epub 2015 Jan 10. Cancer Chemother Pharmacol. 2015. PMID: 25575764 Clinical Trial.
Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
Oki E, Emi Y, Kojima H, Higashijima J, Kato T, Miyake Y, Kon M, Ogata Y, Takahashi K, Ishida H, Saeki H, Sakaguchi Y, Yamanaka T, Kono T, Tomita N, Baba H, Shirabe K, Kakeji Y, Maehara Y. Oki E, et al. Among authors: kato t. Int J Clin Oncol. 2015 Aug;20(4):767-75. doi: 10.1007/s10147-015-0784-9. Epub 2015 Jan 28. Int J Clin Oncol. 2015. PMID: 25627820 Clinical Trial.
[Cetuximab improved the poor performance status of a colorectal cancer patient].
Sakisaka H, Kato T, Kagawa Y, Ishida T, Sato Y, Morimoto Y, Matsushita K, Hashimoto T, Kusama H, Kimura K, Katsura Y, Nitta K, Okishiro M, Takeno A, Nakahira S, Taniguchi H, Egawa C, Takeda Y, Tamura S. Sakisaka H, et al. Among authors: kato t. Gan To Kagaku Ryoho. 2014 Nov;41(12):1776-8. Gan To Kagaku Ryoho. 2014. PMID: 25731326 Japanese.
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.
Matsuda C, Uemura M, Nakata K, Shingai T, Nishimura J, Hata T, Ikenaga M, Takemasa I, Mizushima T, Kato T, Ikeda M, Ohue M, Murata K, Hasegawa J, Satoh T, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Matsuda C, et al. Among authors: kato t. BMC Cancer. 2015 Jun 3;15:452. doi: 10.1186/s12885-015-1476-6. BMC Cancer. 2015. PMID: 26036466 Free PMC article. Clinical Trial.
12,721 results
You have reached the last available page of results. Please see the User Guide for more information.